四十例无法手术的胰腺癌患者被纳入一项多种化疗的前瞻性、随机、对照试验中。19名未接受治疗的对照患者的生存情况与21名接受静脉氟尿嘧啶、环磷酰胺、甲氨蝶呤和长春新碱为期五天的诱导疗法治疗后，在随后每六周间歇期用静脉氟尿嘧啶和丝裂霉素治疗三到五天的患者进行了对比。治疗患者的中位生存期为44周，显著长于对照组9周。在无转移患者中，治疗组的中位生存期为48周，对照组为12周。在有转移患者中，治疗组为30周，对照组为7周。治疗效果良好，似乎能够显著延长生存时间，与以往有或无放疗的化疗报告相比有优势。如果结果确认，这种方案可能在地区综合医院的实践中有用。

Forty patients with inoperable pancreatic cancer were included in a prospective, randomised, controlled trial of multiple chemotherapy. The survival of 19 untreated control patients was compared with that of 21 patients who received an initiation course of intravenous fluorouracil, cyclophosphamide, methotrexate, and vincristine given over five days followed by intravenous fluorouracil and mitomycin given over three or five days at six-week intervals thereafter. Median survival in treated patients was 44 weeks, which was significantly longer than the nine weeks seen in controls. In patients without metastases median survival was 48 weeks in the treated group and 12 weeks in controls. In patients with metastases it was 30 weeks in treated patients and seven weeks in controls. The treatment was well tolerated and seemed to confer a significant prolongation of survival, comparing favourably with previous reports of chemotherapy with or without radiotherapy. If the results are confirmed this regimen may be useful in district general hospital practice.